GFM
FHTX icon

GF Fund Management’s Foghorn Therapeutics FHTX Stock Holding History

GF Fund Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.06K Sell
1,241
-22
-2% -$98 ﹤0.01% 563
2026
Q1 		$6.04K Buy
1,263
+152
+14% +$834 ﹤0.01% 596
2025
Q4 		$6K Sell
1,111
-81
-7% -$367 ﹤0.01% 614
2025
Q3 		$5.83K Sell
1,192
-232
-16% -$1.23K ﹤0.01% 602
2025
Q2 		$6.69K Hold
1,424
– – ﹤0.01% 609
2025
Q1 		$5.2K Buy
1,424
+257
+22% +$1.17K ﹤0.01% 622
2024
Q4 		$5.51K Buy
+1,167
New +$8.5K ﹤0.01% 606

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GF Fund Management's FHTX Position: Q2 2026 in Review

GF Fund Management reduced its Foghorn Therapeutics (FHTX) stake by 1.7% in Q2 2026, selling an estimated $98 and leaving 1,241 shares worth $6.06K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

GF Fund Management first reported a position in FHTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.69K in Q2 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • GF Fund Management held 1,241 shares of Foghorn Therapeutics worth $6.06K as of Q2 2026.
  • GF Fund Management sold 22 Foghorn Therapeutics shares in Q2 2026, an estimated $98.
  • Foghorn Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #563 holding.
  • GF Fund Management first reported a position in Foghorn Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Foghorn Therapeutics position peaked at $6.69K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.